Form 4: KalVista CMO Sells Shares for Tax Obligations

KalVista Pharmaceuticals' Chief Medical Officer, Paul K. Audhya, sold 3,075 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

Summary

• Paul K. Audhya, Chief Medical Officer of KalVista Pharmaceuticals, Inc. (KALV), reported transactions involving the company's common stock.
• On November 17, 2025, 6,447 shares of common stock were acquired through the vesting and settlement of Restricted Stock Units (RSUs).
• On November 18, 2025, 3,075 shares of common stock were sold at a weighted average price of $14.4795 per share.
• This sale was a "sell to cover" transaction solely to satisfy tax withholding obligations related to the RSU vesting and was not a discretionary sale.
• Following these transactions, Mr. Audhya beneficially owns 125,877 shares of KalVista Pharmaceuticals, Inc. common stock directly.
• Two tranches of Restricted Stock Units (RSUs) were involved in the vesting: 2,419 units and 4,028 units. After these transactions, 4,838 RSUs remain for one tranche, and 0 for the other.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation and tax obligations, which are neither inherently positive nor negative for the company's fundamental outlook.

Positives

• The vesting of Restricted Stock Units indicates continued service and alignment of management interests with shareholders.
• The sale was non-discretionary, solely to cover tax withholding obligations, which is a common and expected practice for RSU vesting.

Negatives

• A reduction in direct beneficial ownership of 3,075 shares, although for tax purposes.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Minor, as the transaction is routine and non-discretionary, unlikely to signal a change in management's confidence or the company's prospects.

Key Dates

Recommendation

This Form 4 details a routine, non-discretionary "sell to cover" transaction by a Chief Medical Officer to satisfy tax obligations arising from RSU vesting. Such transactions are common and do not typically reflect a change in the insider's view of the company's prospects or fundamental value. Therefore, it provides no new information that would warrant a change in investment recommendation.

Keywords

KalVista Pharmaceuticals, KALV, Form 4, Insider Transaction, Restricted Stock Units, RSU, Sell to Cover, Chief Medical Officer, Paul K. Audhya, Stock Sale, Tax Withholding